If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
== See also == Market capitalization § Market cap terms, including large-cap and mid-cap Small-cap Microcap stock, including nano-caps List of public corporations by market capitalization Magnificent Seven (stocks) Market price Authorised capital Treasury stock
=== Rayon production === Reaction with ammonium hydroxide can yield tetraamminecopper(II) sulfate and Schweizer's reagent (nonsulphurous), which is used to dissolve cellulose in the industrial production of Rayon.
Centralized market escrow allows a market to close down and "exit" with the buyer's and vendor's cryptocurrency at any time. This has happened on several occasions such as with BlackBank, Evolution, and Wall Street Market. Individual vendors often reach a point of reputation maturity whereby they have sold sufficient product reliably to have gained a significant reputation and accumulated escrowed funds; many may choose to exit with the funds rather than compete at the higher-volume higher-priced matured product level.
In another example, the stable radical TEMPO was attached to the graphene-coated cobalt nanoparticles via a diazonium reaction. The resulting catalyst was then used for the chemoselective oxidation of primary and secondary alcohols.
=== Pain === KOR agonists have been clinically employed as analgesics, with examples including butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, and eptazocine. Unlike MOR agonists, KOR agonists do not cause respiratory depression and have lower abuse potential, but centrally-mediated side effects such as dysphoria, hallucinations, and dissociation have limited their clinical utility. Nalorphine and nalmefene are dual MOR antagonists and KOR agonists used clinically as antidotes for opioid overdose, but the specific role of KOR activation to their efficacy remains uncertain as KOR agonists do not reverse respiratory depression induced by MOR activation and thus cannot serve as standalone antidotes for this purpose. Peripherally selective KOR agonists display analgesic efficacy mediated through anti-inflammatory effects on immune cells and nociceptors. CR665 and difelikefalin (CR845, FE-202845) have been investigated clinically; marking the first peripherally-restricted KOR agonist to reach regulatory approval, though none have yet been approved specifically for pain indication. Recent evidence supports the therapeutic potential of mixed KOR/MOR agonists and KOR-biased ligands as adjuncts to conventional analgesics in inflammatory and cancer pain, with particular promise for chronic neuropathic pain syndromes.
Sources: en.wikipedia.org
Jenner sent a paper reporting his observations to the Royal Society in April 1797. It was not submitted formally and there is no mention of it in the Society's records. Jenner had sent the paper informally to Sir Joseph Banks, the Society's president, who asked Everard Home for his views. Reviews of his rejected report, published for the first time in 1999, were skeptical and called for further vaccinations. Additional vaccinations were performed and in 1798 Jenner published his work entitled An Inquiry into the Causes and Effects of the Variolae Vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire and Known by the Name of Cow Pox. It was an analysis of 23 cases including several individuals who had resisted natural exposure after previous cowpox. It is not known how many Jenner vaccinated or challenged by inoculation with smallpox virus; e.g. Case 21 included 'several children and adults'. Crucially all of at least four whom Jenner deliberately inoculated with smallpox virus resisted it. These included the first and last patients in a series of arm-to-arm transfers. He concluded that cowpox inoculation was a safe alternative to smallpox inoculation, but rashly claimed that the protective effect was lifelong. This last proved to be incorrect. Jenner also tried to distinguish between 'True' cowpox which produced the desired result and 'Spurious' cowpox which was ineffective and/or produced severe reaction.
In the case of large pets, such as dogs and cats, freeze-drying is also the best way to capture the animal's expression as it looked in life (another important concern of owners). Freeze-drying equipment is costly and requires much upkeep. The process is also time-consuming; therefore, freeze-drying is generally an expensive method to preserve an animal. The drawback to this method is that freeze-dried mounts are extremely susceptible to insect damage. This is because they contain large areas of dried tissue (meat and fat) for insects to feed upon. Traditional mounts are far less susceptible because they contain virtually no residual tissues (or none at all). Regardless of how well a taxidermy mount is prepared, all taxidermy is susceptible to insect damage. Taxidermy mounts are targeted by the same beetles and fabric moths that destroy wool sweaters and fur coats and that infest grains and flour in pantries.
Digital Audio Broadcasting (DAB) debuted in some countries in 1998. It transmits audio as a digital signal rather than an analog signal as AM and FM do. DAB has the potential to provide higher quality sound than FM (although many stations do not choose to transmit at such high quality), has greater immunity to radio noise and interference, makes better use of scarce radio spectrum bandwidth and provides advanced user features such as electronic program guides. Its disadvantage is that it is incompatible with previous radios so that a new DAB receiver must be purchased. Several nations have set dates to switch off analog FM networks in favor of DAB / DAB+, notably Norway in 2017 and Switzerland in 2024. A single DAB station transmits a 1,500 kHz bandwidth signal that carries from 9–12 channels of digital audio modulated by OFDM from which the listener can choose. Broadcasters can transmit a channel at a range of different bit rates, so different channels can have different audio quality. In different countries DAB stations broadcast in either Band III (174–240 MHz) or L band (1.452–1.492 GHz) in the UHF range, so like FM reception is limited by the visual horizon to about 40 miles (64 km). HD Radio is an alternative digital radio standard widely implemented in North America. An in-band on-channel technology, HD Radio broadcasts a digital signal in a subcarrier of a station's analog FM or AM signal. Stations are able to multicast more than one audio signal in the subcarrier, supporting the transmission of multiple audio services at varying bitrates.
putative gene A specific nucleotide sequence suspected to be a functional gene based on the identification of its open reading frame. The gene is said to be "putative" in the sense that no function has yet been described for its products.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.